MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
'Throughout 2024, MiNK advanced its mission to bring off-the-shelf iNKT cell therapies to patients fighting hard-to-treat cancers and severe immune-related disorders,' said Dr. Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics. 'We made significant clinical strides, strengthened our manufacturing foundation, and forged strategic alliances. Through disciplined capital management, we are positioned to scale efficiently and seize new collaboration opportunities for value creation. With our rapid AI-driven drug discovery platform generating a world-class library of phosphorylated neoantigens and proprietary TCRs, MiNK is uniquely poised to progress a new standard in oncology and beyond.'
Operational Highlights
Clinical Advancements
Expanding Benefit in Where Standards Fail: Presentations at leading oncology conferences—including AACR IO, ASCO GI, and SITC—demonstrated that AgenT-797 enhanced immune activation, improved checkpoint inhibitor efficacy, and augmented bispecific engagers in heavily pretreated patients and preclinical models. A Phase 2 Investigator-Sponsored Trial (Memorial Sloan Kettering Cancer Center) in second-line advanced gastric cancer (NCT06251973) is actively enrolling. Early data suggest promising activity when combining AgenT-797 with botensilimab/balstilimab (BOT/BAL) and chemotherapy.
Immunologic Activity in Inflammatory Lung Conditions (): Published results in Nature Communications and presented at the American Thoracic Society (ATS) showed AgenT-797's potential in acute respiratory distress, with an approximately 80% survival rate among VV ECMO patients versus 10% in hospital controls. Late-stage trials are designed and planned for upcoming discussion with the regulatory agencies.
Next-Generation iNKT Programs
PRAME-TCR iNKTs: Demonstrated high specificity and potent tumor-killing against intracellular cancer targets resistant to conventional therapies. MiNK's expertise in accessing a proprietary library of phosphorylated peptides and personalized neoantigens supports the generation of high-quality TCRs.
MiNK-215 (IL-15 Armored CAR-iNKT): Robust anti-tumor activity in models of metastatic colorectal cancer, reshaping the immunosuppressive tumor microenvironment.
These data, including exciting findings from AACR IO on the importance of neoantigen targeting, underscore MiNK's commitment to evolving next-generation iNKT treatments that could potentially tackle the most challenging cancer types.
Strategic Growth and Manufacturing Optimization
MiNK's state-of-the-art manufacturing process enables the production of billions of donor-derived iNKT cells per run, scalable to support rapid global distribution, aimed at reducing logistical hurdles, cost, and enhancing patient access.
In October 2024, MiNK entered into a research collaboration with Autonomous Therapeutics to develop precision RNA-iNKT therapies for metastatic tumors. This collaboration is actively underway.
In 2024, MiNK raised $5.8M in private financing and is prioritizing externally funded clinical trials to effectively sustain and advance its iNKT cell programs.
'We believe MiNK Therapeutics is on solid footing to pioneer the next generation of cell therapies,' added Dr. Buell. 'We will continue to pair scientific discipline with operational rigor, a strategy designed to enable value-inflection in 2025 and beyond.'
Financial Highlights
We ended the year with a cash balance of $4.6 million. Cash used in operations for the three and twelve months ended December 31, 2024, was $1.7 million, and $9.6 million, respectively, compared to $3.0 million and $15.8 million for the same periods in 2023.
Net loss for the year ended December 31, 2024 was $10.8 million, or $2.86 per share, compared to net loss for the same period in 2023 of $22.5 million or $6.54 per share.
Summary Consolidated Financial Information
Condensed Consolidated Balance Sheet Data
(in thousands)
(unaudited)
December 31,
2024
2023
Cash and cash equivalents
$
4,577
$
3,367
Total assets
5,721
4,552
Other Financial Information
(in thousands)
(unaudited)
Three months ended December 31,
Year ended December 31,
2024
2023
2024
2023
Cash used in operations
$
1,728
$
3,036
$
9,555
$
15,763
Non-cash expenses
757
1,155
770
3,798
Condensed Consolidated Statements of Operations Data
(in thousands, except per share data)
(unaudited)
Three months ended December 31,
Year ended December 31,
2024
2023
2024
2023
Operating expenses:
Research and development
$
1,406
$
3,311
$
6,336
$
15,490
General and administrative
809
2,189
4,314
7,431
Change in fair value of related party note
288
-
638
-
Operating loss
2,503
5,500
11,288
22,921
Other income, net
(39
)
(41
)
(503
)
(463
)
Net loss
$
2,464
$
5,459
$
10,785
$
22,458
Per common share data, basic and diluted:
Net loss
$
0.62
$
1.58
$
2.86
$
6.54
Weighted average number of common shares outstanding, basic and diluted
3,957
3,456
3,773
3,436
Conference Call
Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada)
Conference ID: 8023784
Webcast
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company's website at https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/s9hd6k7m/.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
About AgenT-797
AgenT-797 is an allogeneic invariant natural killer T (iNKT) cell therapy that harnesses the dual power of innate and adaptive immunity. iNKTs function as 'master regulators,' combining the cytotoxic capabilities of NK cells with T-cell–like antigen recognition and memory. This unique biology enables a robust, pathogen-agnostic immune response that can be directed against hard-to-treat tumors.
Manufactured by MiNK Therapeutics in Lexington, MA, agenT-797 is a scalable, off-the-shelf product designed to provide accessible, transformative treatment options. In clinical trials, agenT-797 can bolster peripheral memory T-cell activation, enhance tumor infiltration, and potentially improve outcomes for patients with solid cancers (Cytryn et al. AACR IO 2024, Oncogene. 2024) and to combat inflammation in critically ill patients with severe respiratory pathology (Nature Communications. 2024).
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, anticipated benefit, plans and timelines of iNKT cells, as well as the collaboration between MiNK and Agenus. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK and Agenus with no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Investor Contact
917-362-1370
investor@minktherapeutics.com
Media Contact
781-674-4428
communications@minktherapeutics.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Why Meta Platforms Stock Is Skyrocketing Today
Key Points Meta Platforms beat second-quarter estimates handily, with EPS surging 38% year over year to $7.14. Meta continues to add to its audience, with daily active users growing 6% year over year. The company will accelerate AI investment into the next year. 10 stocks we like better than Meta Platforms › Shares of Meta Platforms (NASDAQ: META) are flying higher on Thursday, up 12.2% as of 2:53 p.m. ET. Today's jump comes as the S&P 500 was flat and the Nasdaq Composite gained 0.3%. The tech giant reported earnings after markets closed on Wednesday, including a blowout quarter that beat the already high expectations of Wall Street. Meta's ad business is stronger than ever The second-quarter earnings report showed that the company's huge base of daily active users (DAUs) is still growing, up 6% year over year (YOY). This, along with efficiency gains that the company attributed to AI, drove huge growth in earnings and sales. Earnings per share (EPS) jumped 38% YOY to $7.14, well above the analyst consensus estimate of $5.88 for the quarter. Its top-line revenue reached $47.5 billion, a 22% jump YOY, handily beating Wall Street's $44.8 billion target. CEO Mark Zuckerberg explained this success by saying, "The strong performance this quarter is largely thanks to AI unlocking greater efficiency and gains across our ad system." That's a good thing for investors to hear, considering Meta spent $31 billion on AI in the first half of this year alone, and it doesn't plan to stop anytime soon. Chief financial officer Susan Li told investors that Meta expects to ramp up its investments significantly in 2026. Meta looks healthy Meta appears to be firing on all cylinders and reaping the benefits of AI while investing heavily in its future. Its enormous cash flows will allow it to do so more or less indefinitely, or at least until shareholders' appetite wanes. If these sorts of efficiency gains continue, however, I don't see that happening. Even after today's spike, Meta is a buy. Should you invest $1,000 in Meta Platforms right now? Before you buy stock in Meta Platforms, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Meta Platforms wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Meta Platforms. The Motley Fool has a disclosure policy. Why Meta Platforms Stock Is Skyrocketing Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
Nvidia's China Nightmare? H20 Chip Faces Backdoor Allegations in High-Stakes Trade Showdown
China's been turning up the heat on Nvidia (NASDAQ:NVDA), and not in a good way. This week, the country's top internet watchdog summoned Nvidia reps over what it calls serious security risks tied to the H20 chipa product Nvidia designed specifically to meet U.S. export rules. State media pulled no punches either. In a commentary published Friday, the People's Daily warned of potential chip backdoors triggering a nightmare, saying it couldn't allow infected semiconductors into its digital infrastructure. Nvidia responded firmly: Cybersecurity is critically important to us, adding that its chips don't contain any remote access pathways. Still, in today's geopolitical climate, that reassurance may not be enough. Warning! GuruFocus has detected 5 Warning Signs with NVDA. Here's where things get messier. Just a few weeks ago, the U.S. agreed to lift restrictions on H20 sales to China as part of a broader deal involving rare-earth magnetsmaterials critical for everything from smartphones to fighter jets. Commerce Secretary Howard Lutnick had framed the H20 resumption as a meaningful breakthrough after bilateral talks in London, and Treasury Secretary Scott Bessent said the magnet issue was solved. But with Beijing now putting the H20 back under the microscope, it's unclear whether Nvidia has actually received the licenses it needs to ship the chips. And if China decides the H20 isn't up to pareither technically or politicallythose sales may stall before they even start. Meanwhile, CEO Jensen Huang has been walking a tightrope. Fresh off a high-profile visit to Beijing, Huang praised China's AI momentum and national champions like DeepSeek, all while pushing back on the idea that Nvidia would ever install surveillance backdoors into its products. He called the suggestion not only false, but bad business. Still, the reality is this: Nvidia's H20, already weaker than its flagship GPUs, now faces a political test that could matter more than its specs. Investors watching the tech standoff might want to pay close attention to what happens nextbecause this chip is turning into a geopolitical bargaining chip. This article first appeared on GuruFocus.
Yahoo
14 minutes ago
- Yahoo
2 Top Artificial Intelligence Stocks to Buy in August
Key Points Micron Technology trades at just 9.2 times forward earnings despite being Nvidia's preferred memory supplier. Alphabet runs businesses like YouTube, Waymo, Android, and Google Cloud, giving it many paths to future growth. Both stocks look undervalued next to their AI peers despite playing crucial roles in the artificial intelligence (AI) revolution. 10 stocks we like better than Alphabet › Many artificial intelligence (AI) specialists have seen their stocks skyrocket in the last couple of years. At the same time, some of the best names in the AI boom have been left behind. In particular, memory chip maker Micron Technology (NASDAQ: MU) and online services giant Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) look like fantastic buys right now. Their modest stock valuations don't reflect their massive growth opportunities. So if you're looking for an AI stock to buy in August, you should give Google's parent company and Micron another look. Read on and I'll get you started. Micron Technology looks like a bargain right now The memory chip market is notoriously cyclical. The handful of leading chip suppliers never seem to be ready when another tech trend results in massive demand for digital memory (smartphones, AI, and increasingly computerized cars are just three examples). Then they build out their manufacturing facilities until the demand driver fades out or the new supply simply grows too large. That's where unit prices drop, the memory industry goes into a mini-recession, and investors wait for the next surge in demand. You can see these cycles on Micron's stock chart, with a semi-predictable roller coaster ride with peaks and valleys. Importantly, each new top tends to be much higher than the last one. From that perspective, the AI-driven memory boom has been going on for about two years now. Some of the industry's cycles have seen two-year upswings followed by similar-sized downswings. And Micron's stock has gained 61% in the past two years -- maybe it's time for a correction? Some market makers sure seem to feel that way. Micron's stock trades at just 9.2 times forward earnings estimates today. Its price-to-earnings-to-growth (PEG) ratio is a minuscule 0.2. As a reminder, a PEG ratio around 1.0 indicates a fair valuation, in terms of proven profits and upcoming growth. Values in Micron's range suggest that investors aren't convinced by optimistic growth targets, or worried about the company's financial future, or both. But Micron's sales rose by 58% in the past two years, while trailing free cash flows swung from a $4.7 billion negative reading to $1.9 billion of positive cash profits. Micron is the preferred memory provider for Nvidia's (NASDAQ: NVDA) latest and greatest AI accelerators. Modern smartphones ship with lots of extra memory in order to handle their built-in AI functions. In short, the growth catalysts just keep coming. Micron is playing a very active part in the AI revolution, but the stock is acting like it's just another short-lived upswing. If you believe that AI will drive business growth for years to come, Micron should be on your short list of stocks to buy right now. Alphabet is playing the long game Alphabet's stock has gained just 3% in 2025. That's far behind Nvidia's 31%, or even the 8% increase in the S&P 500 (SNPINDEX: ^GSPC) market index. And in the valuation corner, the Google parent's stock could double in price and still look affordable next to market darlings like Nvidia. That approximate ratio holds firm across many different valuation metrics, from price-to-earnings to cash-flow valuations. Moreover, I think of Nvidia as a one-trick pony while Alphabet always has another trick up its sleeve. Let me explain. Sure, Nvidia's pony is an incredibly impressive racehorse that has taken Nvidia's business results to lofty heights in recent years. Still, I wonder what might happen to its high-flying stock if and when another chip maker starts winning large AI system contracts under Nvidia's nose. I'm not even speculating here. Longtime Nvidia rival Advanced Micro Devices (NASDAQ: AMD) already offers a competitive solution in its Instinct product range. Furthermore, major buyers such as Alphabet and Amazon are designing their own custom AI chips nowadays. I'm not convinced that Nvidia's golden years will last much longer. At the same time, Alphabet was built to last. The online search and advertising market won't be there forever, and the Google parent has been preparing for that sea change since forever. Alright, since 2014. Same thing in this ever-changing tech sector. Alphabet runs a leading media-streaming platform (YouTube), an early robotaxi specialist (Waymo), and the world's busiest mobile platform (Android). The Google Cloud service isn't dominating its market, but puts up a serious fight while developing cloud-based AI tools. Looking ahead, the company's next big idea might be medical research, or remote internet access, or maybe something I haven't heard of yet. Either way, Alphabet plans to stick around for decades, and its stock is on fire sale right now. Alphabet is pretty much always a decent buy -- it's just an even better idea these days. Should you invest $1,000 in Alphabet right now? Before you buy stock in Alphabet, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Alphabet wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Anders Bylund has positions in Alphabet, Amazon, Micron Technology, and Nvidia. The Motley Fool has positions in and recommends Advanced Micro Devices, Alphabet, Amazon, and Nvidia. The Motley Fool has a disclosure policy. 2 Top Artificial Intelligence Stocks to Buy in August was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
